A Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination With Chemotherapy and Other Investigational Agents in First-line Non-small Cell Lung Cancer
A Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination With Chemotherapy and Other Investigational Agents in First-line Non-small Cell Lung Cancer
This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC).
This study includes two substudies (substudy A and substudy B) that will recruit participants according to histological subtypes due to differences in chemotherapy choice for standard-of-care and type of NSCLC.
Each substudy contains a Phase 2 part followed by a Phase 3 part. In the Phase 2 part, participants will be randomized to one of two dose levels of pumitamig (also known as BNT327, BMS-986545, or PM8002) plus chemotherapy (Arm 1 and Arm 2). In the Phase 3 part, participants will be randomized to pumitamig plus chemotherapy (Arm 3) or pembrolizumab plus chemotherapy (Arm 4). In China, additional participants will be enrolled into the Phase 2 part of each substudy to receive pumitamig plus chemotherapy (Arm 1A) to further evaluate the selected Phase 3 dose.
For the Phase 3 part of both substudies, an independent data monitoring committee (IDMC) and a blinded Independent Central Review (BICR) will be established. The IDMC will provide independent review of the data during the study as needed and the BICR will review all available tumor assessment scans for all treated participants and will confirm the progression of disease, if applicable.
The planned study duration per study participant is up to 64 months.
Key Inclusion Criteria:
Key Exclusion Criteria:
Have histologically or cytologically confirmed NSCLC with small-cell lung cancer or neuroendocrine histologic component.
Have received any of the following therapies or drugs within the noted time intervals prior to study treatment:
Have uncontrolled hypertension or poorly controlled diabetic conditions prior to study treatment.
Have a serious or non-healing wound, or (incompletely healed) bone fracture. This includes history (within 6 months prior to study entry) or risk of abdominal fistula, tracheoesophageal fistula, gastrointestinal perforation, or intra-abdominal abscess or esophageal and gastric varices. In addition, the participant must have undergone correction (or spontaneous healing) of the perforation/fistula and/or the underlying process causing fistula/perforation.
Participants with significant risk of hemorrhage (per investigator clinical judgment).
Participants have superior vena cava syndrome or symptoms of spinal cord compression.
NOTE: Other protocol defined Inclusion/Exclusion criteria apply.
patients@biontech.de+49 6131 9084 ext. 0
Birmingham, Alabama 35223, United States
La Jolla, California 92093, United States
Iowa City, Iowa 52242, United States
Frederick, Maryland 21704, United States
Hastings, Nebraska 68901-4470, United States
Paramus, New Jersey 07652, United States
Hendersonville, North Carolina 28792, United States
Cleveland, Ohio 44111, United States
Nashville, Tennessee 37232, United States
Houston, Texas 77090, United States
São José do Vale do Rio Preto, 15090-000, Brazil
Bordeaux, 33000, France
Bordeaux, 33076, France
Créteil, 94010, France
La Tronche, 38700, France
Saint-Herblain, 44805, France
Toulon, 83000, France
Tbilisi, 0144, Georgia
Immenhausen, 34376, Germany
Bologna, 40138, Italy
Meldola, 47014, Italy
Milan, 20132, Italy
Roma, 00144, Italy
Siena, 53100, Italy
Nagaizumi-chō, 411-8777, Japan
Osaka, 541-8567, Japan
Gdansk, 80-211, Poland
Craiova, 200542, Romania
Badalona, 08916, Spain
Las Palmas de Gran Canaria, 35016, Spain
Valencia, 46026, Spain
Lausanne, 1011, Switzerland
Nakhon Nayok, 26120, Thailand
Ankara, 06200, Turkey (Türkiye)
Samsun, 55280, Turkey (Türkiye)
Bath, BA1 3NG, United Kingdom
Brighton, BN2 5BE, United Kingdom
Chelsea, SW3 6JJ, United Kingdom
Glasgow, G12 0YN, United Kingdom
London, SM2 5PT, United Kingdom
Norwich, NR4 7UY, United Kingdom
Oxford, OX3 7LJ, United Kingdom
Preston, PR2 9HT, United Kingdom
Sheffield, S10 2SJ, United Kingdom
Taunton, TA1 5DA, United Kingdom